Promethera is committed to develop life-changing new cell therapies for patients suffering from serious liver diseases. As an innovator in the emerging field of cell-based medicines, Promethera is driven by the ambition of creating a diverse portfolio of drug candidates with partners and on our own account. This vision has attracted a broad range of European and Asian institutional and corporate investors throughout the Company’s development steps as a privately-held organization.
* Essentially HNWI and private investors
** up to 11,2% after conversion of receivable in 2018 or earlier
Promethera has garnered the support of important corporate venture funds including Shire, Boehringer Ingelheim, Mitsui, Mitsubishi and specialized biotech investors such as Vesalius Biocapital and Fund+. Most recently the company gained capital from strategic Japanese and Korean investors, further enabling Promethera’s vision of treating patients worldwide.
Since inception, Promethera has raised EUR 48.6 million raised in equity not including non-dilutive support from the Walloon region of Belgium through grants and recoverable cash advances.
Current investors overview:
Founders & Management
Venture Capital Funds
Life Science Research Partners
Details on investors:
Vesalius Biocapital S.A.
SICAR is a venture capital fund focusing on the creation and growth of European non-quoted life science companies. The Fund invests in those areas that have highest profit potential: new therapeutics, cutting-edge medical devices, innovative drug delivery technologies as well as (non-) clinical diagnostics and screening tests with a high utility level.
Sopartec is the Technology Transfer Office and fully owned subsidiary of the Université catholique de Louvain (UCL). In close cooperation with the UCL Research Administration (ADRE - Administration de la Recherche), Sopartec is in charge of the management and commercialization of the UCL Intellectual Property for the benefit of society, the regional economy, the inventors and the University. Sopartec is also managing the Vives fund, a €15 M seed investment fund dedicated to technology companies exploiting the R&D performed in UCL.
Fund+ is an open-ended Fund for long term equity investment in innovative Life Sciences companies with a focus on Belgium. We want to create sustainable shareholders value, contribute to the development of a leadership position in the Life Sciences sector and generate a tangible, beneficial societal impact.
(Société Régionale d'Investissement de Wallonie) Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st Century.
The Boehringer Ingelheim Venture Fund was formed in March 2010 to invest in biotechnology and start-up companies to help drive innovation in medical science. These may include – but are not limited to - novel technologies to address so far undrugable targets, new generation vaccines and new biological entities, such as antibody-dependent oncolysis. Novel therapeutic targets and disease-related biomarkers, as well as new approaches in regenerative medicine, are an additional focus.
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
Mitsui Global Investment (MGI) is a subsidiary of Mitsui & Co. Ltd. which invests in opportunities that have potential for growth. Headquartered in Tokyo, the company has offices in Silicon Valley, New York, Shanghai, Beijing, Mumbai and London (Alliance Team office) and its investments reach beyond these geographical barriers, reflecting a diversified global portfolio.
Mitsubishi UFJ, Japan’s largest bank, invests in healthcare, electronics, and high technology investments through its venture capital arm Mitsubishi UFJ Capital Co., Ltd.
LifeLiver Co., Ltd., a subsidiary of HLB Co. Ltd. (South Korea), develops a new generation bio-artificial liver (the BAL system) as a medical device for patients with acute liver failure. The company is based in the Seoul area in South Korea.
Cell Innovation Partners, L.P. a joint initiative between Reprocell Inc. (Japan) and Shinsei Bank Group (Japan), was launched in 2014 with the aim of becoming a strategic investor in regenerative medicine and creating next-generation stem cell therapy businesses.
SMS Investments is a Luxemburg based subsidiary of the German SMS group, a family-owned group of companies active in plant and machinery construction for the processing of steel and NF metals. Via its internal asset management activities SMS group invests into a diversified portfolio consisting of liquid assets as well as of private equity and venture capital.